LJ570 manufacturers
- LJ570
-
- $148.00 / 1mg
-
2024-10-28
- CAS:2252488-69-8
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| Product Name: | LJ570 | | Synonyms: | LJ570;[1,1'-Biphenyl]-4-propanoic acid, α-([1,1'-biphenyl]-4-yloxy)-, (αS)-;1,1'-Biphenyl]-4-propanoic acid,α-([1,1'-biphenyl]-4-yloxy)-,(αS)-;inhibit,Peroxisome proliferator-activated receptors,LJ-570,LJ 570,LJ570,Inhibitor,PPAR;(2S)-2-{[1,1'-biphenyl]-4-yloxy}-3-{[1,1'-biphenyl]-4-yl}propanoic acid | | CAS: | 2252488-69-8 | | MF: | C27H22O3 | | MW: | 394.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2252488-69-8.mol |  |
| | LJ570 Chemical Properties |
| Boiling point | 601.0±55.0 °C(Predicted) | | density | 1.185±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 2.96±0.10(Predicted) |
| | LJ570 Usage And Synthesis |
| Description | LJ570 is the first PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. LJ570 is a potent partial agonist of both PPARα and γ subtypes. LJ570 inhibited the Cdk5-mediated phosphorylation of PPARγ at serine 273 that is currently considered the mechanism by which some PPARγ partial agonists exert antidiabetic effects similar to thiazolidinediones, without showing their typical side effects. LJ570 may be useful for treatment of dyslipidemic type 2 diabetes. | | target | LJ570 is the first PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. |
| | LJ570 Preparation Products And Raw materials |
|